Management of systemic AL amyloidosis: Recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group

N. Weber, P. Mollee, B. Augustson, R. Brown, L. Catley, J. Gibson, S. Harrison, P. J. Ho, N. Horvath, W. Jaksic, D. Joshua, H. Quach, A. W. Roberts, A. Spencer, J. Szer, D. Talaulikar, B. To, A. Zannettino, H. M. Prince

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Systemic AL amyloidosis is a plasma cell dyscrasia with a characteristic clinical phenotype caused by multi-organ deposition of an amyloidogenic monoclonal protein. This condition poses a unique management challenge due to the complexity of the clinical presentation and the narrow therapeutic window of available therapies. Improved appreciation of the need for risk stratification, standardised use of sensitive laboratory testing for monitoring disease response, vigilant supportive care and the availability of newer agents with more favourable toxicity profiles have contributed to the improvement in treatment-related mortality and overall survival seen over the past decade. Nonetheless, with respect to the optimal management approach, there is a paucity of high-level clinical evidence due to the rarity of the disease, and enrolment in clinical trials is still the preferred approach where available. This review will summarise the Clinical Practice Guidelines on the Management of Systemic Light Chain (AL) Amyloidosis recently prepared by the Medical Scientific Advisory Group of the Myeloma Foundation of Australia. It is hoped that these guidelines will assist clinicians in better understanding and optimising the management of this difficult disease.

LanguageEnglish
Pages371-382
Number of pages12
JournalInternal Medicine Journal
Volume45
Issue number4
DOIs
Publication statusPublished - 1 Apr 2015

Keywords

  • AL
  • Amyloidosis
  • Light chain
  • Plasma cell

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Weber, N. ; Mollee, P. ; Augustson, B. ; Brown, R. ; Catley, L. ; Gibson, J. ; Harrison, S. ; Ho, P. J. ; Horvath, N. ; Jaksic, W. ; Joshua, D. ; Quach, H. ; Roberts, A. W. ; Spencer, A. ; Szer, J. ; Talaulikar, D. ; To, B. ; Zannettino, A. ; Prince, H. M. / Management of systemic AL amyloidosis : Recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. In: Internal Medicine Journal. 2015 ; Vol. 45, No. 4. pp. 371-382.
@article{35d1c874949e46cca870814bccf8d810,
title = "Management of systemic AL amyloidosis: Recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group",
abstract = "Systemic AL amyloidosis is a plasma cell dyscrasia with a characteristic clinical phenotype caused by multi-organ deposition of an amyloidogenic monoclonal protein. This condition poses a unique management challenge due to the complexity of the clinical presentation and the narrow therapeutic window of available therapies. Improved appreciation of the need for risk stratification, standardised use of sensitive laboratory testing for monitoring disease response, vigilant supportive care and the availability of newer agents with more favourable toxicity profiles have contributed to the improvement in treatment-related mortality and overall survival seen over the past decade. Nonetheless, with respect to the optimal management approach, there is a paucity of high-level clinical evidence due to the rarity of the disease, and enrolment in clinical trials is still the preferred approach where available. This review will summarise the Clinical Practice Guidelines on the Management of Systemic Light Chain (AL) Amyloidosis recently prepared by the Medical Scientific Advisory Group of the Myeloma Foundation of Australia. It is hoped that these guidelines will assist clinicians in better understanding and optimising the management of this difficult disease.",
keywords = "AL, Amyloidosis, Light chain, Plasma cell",
author = "N. Weber and P. Mollee and B. Augustson and R. Brown and L. Catley and J. Gibson and S. Harrison and Ho, {P. J.} and N. Horvath and W. Jaksic and D. Joshua and H. Quach and Roberts, {A. W.} and A. Spencer and J. Szer and D. Talaulikar and B. To and A. Zannettino and Prince, {H. M.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1111/imj.12566",
language = "English",
volume = "45",
pages = "371--382",
journal = "Australian and New Zealand Journal of Medicine",
issn = "1444-0903",
publisher = "Wiley-Blackwell",
number = "4",

}

Weber, N, Mollee, P, Augustson, B, Brown, R, Catley, L, Gibson, J, Harrison, S, Ho, PJ, Horvath, N, Jaksic, W, Joshua, D, Quach, H, Roberts, AW, Spencer, A, Szer, J, Talaulikar, D, To, B, Zannettino, A & Prince, HM 2015, 'Management of systemic AL amyloidosis: Recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group', Internal Medicine Journal, vol. 45, no. 4, pp. 371-382. https://doi.org/10.1111/imj.12566

Management of systemic AL amyloidosis : Recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. / Weber, N.; Mollee, P.; Augustson, B.; Brown, R.; Catley, L.; Gibson, J.; Harrison, S.; Ho, P. J.; Horvath, N.; Jaksic, W.; Joshua, D.; Quach, H.; Roberts, A. W.; Spencer, A.; Szer, J.; Talaulikar, D.; To, B.; Zannettino, A.; Prince, H. M.

In: Internal Medicine Journal, Vol. 45, No. 4, 01.04.2015, p. 371-382.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Management of systemic AL amyloidosis

T2 - Australian and New Zealand Journal of Medicine

AU - Weber, N.

AU - Mollee, P.

AU - Augustson, B.

AU - Brown, R.

AU - Catley, L.

AU - Gibson, J.

AU - Harrison, S.

AU - Ho, P. J.

AU - Horvath, N.

AU - Jaksic, W.

AU - Joshua, D.

AU - Quach, H.

AU - Roberts, A. W.

AU - Spencer, A.

AU - Szer, J.

AU - Talaulikar, D.

AU - To, B.

AU - Zannettino, A.

AU - Prince, H. M.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Systemic AL amyloidosis is a plasma cell dyscrasia with a characteristic clinical phenotype caused by multi-organ deposition of an amyloidogenic monoclonal protein. This condition poses a unique management challenge due to the complexity of the clinical presentation and the narrow therapeutic window of available therapies. Improved appreciation of the need for risk stratification, standardised use of sensitive laboratory testing for monitoring disease response, vigilant supportive care and the availability of newer agents with more favourable toxicity profiles have contributed to the improvement in treatment-related mortality and overall survival seen over the past decade. Nonetheless, with respect to the optimal management approach, there is a paucity of high-level clinical evidence due to the rarity of the disease, and enrolment in clinical trials is still the preferred approach where available. This review will summarise the Clinical Practice Guidelines on the Management of Systemic Light Chain (AL) Amyloidosis recently prepared by the Medical Scientific Advisory Group of the Myeloma Foundation of Australia. It is hoped that these guidelines will assist clinicians in better understanding and optimising the management of this difficult disease.

AB - Systemic AL amyloidosis is a plasma cell dyscrasia with a characteristic clinical phenotype caused by multi-organ deposition of an amyloidogenic monoclonal protein. This condition poses a unique management challenge due to the complexity of the clinical presentation and the narrow therapeutic window of available therapies. Improved appreciation of the need for risk stratification, standardised use of sensitive laboratory testing for monitoring disease response, vigilant supportive care and the availability of newer agents with more favourable toxicity profiles have contributed to the improvement in treatment-related mortality and overall survival seen over the past decade. Nonetheless, with respect to the optimal management approach, there is a paucity of high-level clinical evidence due to the rarity of the disease, and enrolment in clinical trials is still the preferred approach where available. This review will summarise the Clinical Practice Guidelines on the Management of Systemic Light Chain (AL) Amyloidosis recently prepared by the Medical Scientific Advisory Group of the Myeloma Foundation of Australia. It is hoped that these guidelines will assist clinicians in better understanding and optimising the management of this difficult disease.

KW - AL

KW - Amyloidosis

KW - Light chain

KW - Plasma cell

UR - http://www.scopus.com/inward/record.url?scp=84964216447&partnerID=8YFLogxK

U2 - 10.1111/imj.12566

DO - 10.1111/imj.12566

M3 - Review article

VL - 45

SP - 371

EP - 382

JO - Australian and New Zealand Journal of Medicine

JF - Australian and New Zealand Journal of Medicine

SN - 1444-0903

IS - 4

ER -